IDYA News & Events

Ideaya Biosciences announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE892 as a monotherapy agent and in combination with IDE397, Ideaya's MAT2A inhibitor, in mid-2026. Dual inhibition of IDE892 and IDE397 has demonstrated durable and well-tolerated tumor regressions in preclinical MTAP-deleted tumor models, including in NSCLC.

Ideaya Biosciences announced that the first patient has been enrolled in its Phase 1 dose escalation/expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company is planning to evaluate safety, tolerability and PK of IDE034 as a monotherapy in the Phase 1 trial, and also plans to test combinations with agents that target the DNA damage response pathway, such as their proprietary PARG inhibitor, IDE161. Dosing of the first patient with IDE034 triggers a $5M milestone payment from Ideaya to Biocytogen, pursuant to the option and license agreement between the companies.

Ideaya Biosciences (IDYA) announced the appointment of Theodora Ross into the newly created role of chief development officer. In this role, Ross will be responsible for leading early clinical development for Ideaya's emerging oncology pipeline and play a role in guiding the company's long-term R&D strategy. Ross joins Ideaya from AbbVie (ABBV), where she served as VP, head of early oncology R&D and site head for the Bay Area.